Clinical Trials Browser

Phase 3 × Endometrial Neoplasms × 1 year × Clear all

NCT05256225 2026-03-18

Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma

Phase 3 Recruiting

Neoplasms, Endometrial Neoplasms

NCT03914612 2026-03-17

Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer

Phase 3 Active not recruiting

813 enrolled 16 charts 1 FDA

GynecologicSarcoma

Carcinosarcoma, Endometrial Neoplasms

NCT06952504 2026-03-13

TroFuse-033

Phase 3 Recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Endometrial Neoplasms

NCT06989112 2026-03-12

DE-01

Phase 3 Recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Uterine Neoplasms, Endometrial Neoplasms

NCT07286331 2026-03-11

A Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Recurrent Endometrial Cancer (BEHOLD-Endometrial01)

Phase 3 Not yet recruiting

Endometrial Neoplasms

NCT07198074 2026-03-10

Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer

Phase 3 Recruiting

Endometrial Neoplasms

NCT07044336 2026-03-05

Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)

Phase 3 Recruiting

Neoplasm Metastasis, Uterine Neoplasms, Endometrial Neoplasms

NCT07166094 2026-03-03

RAINFOL-03

Phase 3 Recruiting

Recurrence, Endometrial Neoplasms

NCT07022483 2026-02-04

Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer

Phase 3 Recruiting

Neoplasms, Endometrial Neoplasms

NCT03884101 2026-02-02

LEAP-001

Phase 3 Completed

842 enrolled 25 charts

Endometrial Neoplasms

NCT06340568 2026-02-02

Fern-EC-01

Phase 3 Recruiting

Endometrial Neoplasms

NCT06712472 2026-01-20

RAINBO-RED

Phase 3 Recruiting

Endometrial Neoplasms

NCT06746116 2026-01-16

DUoENDE

Phase 3 Active not recruiting

Endometrial Neoplasms

NCT06486441 2026-01-15

ASCENT-GYN-01

Phase 3 Active not recruiting

Endometrial Neoplasms

NCT06132958 2026-01-09

TroFuse-005

Phase 3 Active not recruiting

Endometrial Neoplasms

NCT04269200 2025-12-23

DUO-E

Phase 3 Active not recruiting

805 enrolled 18 charts 1 FDA

Endometrial Neoplasms

NCT05201547 2025-12-04

DOMENICA

Phase 3 Active not recruiting

Neoplasm Metastasis, Endometrial Neoplasms

NCT06007586 2025-12-04

Prevention and Treatment of CINV Caused by TC Regimen in Gynecological Malignant Tumor Patients

Phase 3 Completed

Uterine Cervical Neoplasms, Fallopian Tube Neoplasms, Ovarian Neoplasms, Vomiting, Endometrial Neoplasms

NCT03517449 2025-06-15

MK-3475-775

Phase 3 Completed

827 enrolled 18 charts 1 FDA

Parkinson Disease 4, Autosomal Dominant Lewy Body, Endometrial Neoplasms

NCT04634877 2025-06-09

KEYNOTE-B21

Phase 3 Active not recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Endometrial Neoplasms

NCT05078047 2025-06-05

MOIO

Phase 3 Recruiting

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & Neck

Esophageal Squamous Cell Carcinoma, Carcinoma, Basal Cell, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Melanoma, Carcinoma, Merkel Cell, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT03603184 2025-05-09

AtTEnd

Phase 3 Completed

Neoplasms, Endometrial Neoplasms

NCT05763667 2025-04-24

Pilot: Intraoperative TAP Block and Post-operative Pain Control for Minimally Invasive Hysterectomy for Endometrial Cancer

Phase 3 Completed

Endometrial Hyperplasia, Pain, Postoperative, Endometrial Neoplasms